Perceptive Advisors LLC Acquires 1,000,000 Shares of Immatics N.V. $IMTX

Perceptive Advisors LLC raised its holdings in Immatics N.V. (NASDAQ:IMTX) by 10.7% during the fourth quarter, Holdings Channel.com reports. The fund owned 10,383,456 shares of the company’s stock after purchasing an additional 1,000,000 shares during the period. Immatics comprises about 1.9% of Perceptive Advisors LLC’s holdings, making the stock its 13th largest holding. Perceptive Advisors LLC owned approximately 0.09% of Immatics worth $109,026,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Vanguard Personalized Indexing Management LLC boosted its stake in Immatics by 3.7% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 49,374 shares of the company’s stock valued at $518,000 after acquiring an additional 1,739 shares during the last quarter. Bank of America Corp DE boosted its stake in Immatics by 166.0% in the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after acquiring an additional 2,231 shares during the last quarter. Barclays PLC boosted its position in shares of Immatics by 11.4% during the fourth quarter. Barclays PLC now owns 28,185 shares of the company’s stock worth $296,000 after purchasing an additional 2,874 shares in the last quarter. Quarry LP bought a new position in shares of Immatics during the fourth quarter worth $84,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Immatics by 18.2% during the fourth quarter. The Manufacturers Life Insurance Company now owns 55,300 shares of the company’s stock worth $557,000 after purchasing an additional 8,500 shares in the last quarter. 64.41% of the stock is owned by institutional investors.

Immatics Trading Up 4.7%

IMTX opened at $9.52 on Thursday. The stock has a market capitalization of $1.28 billion, a P/E ratio of -4.78 and a beta of 1.30. Immatics N.V. has a 12 month low of $5.05 and a 12 month high of $12.41. The firm’s fifty day simple moving average is $10.72 and its 200 day simple moving average is $10.22.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. The business had revenue of $8.81 million during the quarter, compared to analyst estimates of $9.79 million. On average, equities research analysts predict that Immatics N.V. will post -1.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IMTX. Wall Street Zen cut shares of Immatics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Jefferies Financial Group began coverage on shares of Immatics in a research report on Monday, March 16th. They set a “buy” rating and a $18.00 price target on the stock. TD Cowen began coverage on shares of Immatics in a research report on Tuesday, April 28th. They set a “buy” rating on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Immatics in a research report on Tuesday, June 9th. Finally, Mizuho set a $25.00 price target on shares of Immatics in a research report on Thursday, February 19th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.80.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.